MAP2K1 and infection: Our previous studies and others’ have demonstrated that targeted inhibition of mammalian protein kinases MEK1/2 is a promising therapeutic strategy to reduce detrimental inflammation during the context of lung injury and infection (Schuh and Pahl, 2009; Long et al., 2017a; Long et al., 2017b).